At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 27 enrolled
Drug / intervention
Cisplatin +2 moredrug
Likely dose
Cisplatin 60 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study Of Sunitinib In Combination With S-1 And Cisplatin In Patients With Advanced Or Metastatic Gastric Cancer
In Brief
A Phase 1 clinical trial evaluating Cisplatin, S-1, and 1 other intervention for Stomach Neoplasms. Completed, enrolled 27 participants across 3 sites.
Detailed Summary
To assess the maximal tolerated dose (MTD) and overall safety of sunitinib when administered in combination with S-1 and Cisplatin in patients with advanced/metastatic gastric cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStomach Neoplasms
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2007
First PostedNov 2007
Primary CompletionJul 2009
Study CompletionMar 2014
TodayJul 2026
First PostedNov 5, 2007
Enrollment StartNov 1, 2007
Primary CompletionJul 1, 2009
Study CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 18.7 years ago
Interventions
Cisplatindrug
Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
S-1drug
S-1 80 mg/m2 on days 1-21 of each 28 day cycle
Sunitinibdrug
Sunitinib 25 mg, 37.5 mg and 50 mg daily S-1 80 mg/m2 on days 1-21 of each 28 day cycle Cisplatin 60 mg/m2 on day 1 of each 28 day cycle